A. Manipular el sistema oxitocinérgico, a través de antagonistas y agonistas de los
receptores de OT, para evidenciar las alteraciones inducidas por la exposición repetida a anfetamina sobre este sistema, en relación con el RAS cerebral.
B. Estudiar los cambios inducidos por anfetamina sobre los sistemas vasopresinérgico
y serotoninérgico en relación con el RAS cerebral.
C. Caracterizar las alteraciones sobre receptores de Ang II, vías de señalización así
130
BIBLIOGRAFÍA
1. Ando, H., et al., Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke, 2004. 35(7): p. 1726-31.
2. Nishimura, Y., et al., Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors. Brain Res, 2000. 871(1): p. 29-38.
3. Saavedra, J.M., E. Sanchez-Lemus, and J. Benicky, Blockade of brain angiotensin
II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications. Psychoneuroendocrinology, 2011. 36(1): p. 1-18.
4. Benicky, J., et al., Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Mol Neurobiol, 2009. 29(6-7): p. 781-92.
5. Bregonzio, C., et al., Anti-inflammatory effects of angiotensin II AT1 receptor antagonism prevent stress-induced gastric injury. Am J Physiol Gastrointest Liver Physiol, 2003. 285(2): p. G414-23.
6. Sanchez-Lemus, E., et al., Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland. Endocrinology, 2008. 149(10): p. 5177-88.
7. Chevillard, C. and J.M. Alexandre, In vitro effects on cardiac norepinephrine of angiotensin II and of two indirectly acting sympathomimetic amines (amphetamine and tyramine). A study of their combinations. Eur J Pharmacol, 1972. 19(2): p. 223-
30.
8. Robinson, T.E. and B. Kolb, Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. Eur J Neurosci, 1999. 11(5): p. 1598-604.
9. Salsbury, C.A. and R.B. Wayland, The uses and misuses of amphetamines. Med Leg Bull, 1966. 15(4): p. 1-9.
10. Hutson, P.H., et al., Preclinical pharmacology of amphetamine: implications for the treatment of neuropsychiatric disorders. Pharmacol Ther, 2014. 143(3): p. 253-
64.
11. Ahmann, P.A., et al., Placebo-controlled evaluation of amphetamine mixture- dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects. Pediatrics, 2001. 107(1): p. E10.
12. Goodman and Gilman, 5-hidroxitriptamina (serotonina) y dopamina. Sanders-
Bush, E. y Hazelwood, L., in Las bases farmacológicas de la terapéutica, L.L. Brunton, Editor. 2012, Mc Graw-Hill.
13. Moore, K.E., The actions of amphetamine on neurotransmitters: a brief review.
Biol Psychiatry, 1977. 12(3): p. 451-62.
14. Tigerstedt, R. and P.G. Bergman, Niere und Kreislauf. Scand.Arch.Physiol, 1898(8): p. 223-271.
15. Braun-Menendez, E., et al., The substance causing renal hypertension. J Physiol, 1940. 98(3): p. 283-98.
16. Page, I.H. and O.M. Helmer, Angiotonin-Activator, Renin- and Angiotonin-
Inhibitor, and the Mechanism of Angiotonin Tachyphylaxis in Normal, Hypertensive, and Nephrectomized Animals. J Exp Med, 1940. 71(4): p. 495-519.
17. de Gasparo, M., et al., International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev, 2000. 52(3): p. 415-72.
131 18. Inagami, T. and S. Eguchi, Angiotensin II-mediated vascular smooth muscle cell
growth signaling. Braz J Med Biol Res, 2000. 33(6): p. 619-24.
19. Timmermans, P.B., et al., Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev, 1993. 45(2): p. 205-51.
20. Fitts, D.A., et al., Losartan blocks drinking and cFos expression induced by central ornithine vasotocin in rats. Physiol Behav, 2005. 86(4): p. 573-7.
21. Dinh, D.T., et al., Angiotensin receptors: distribution, signalling and function. Clin Sci (Lond), 2001. 100(5): p. 481-92.
22. Goodman and Gilman, Angiotensina. In: Brunton, L.L, JSL. Parker, L.K. Las bases farmacológicas de la terapéutica. 2007.
23. Lavoie, J.L. and C.D. Sigmund, Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system. Endocrinology, 2003. 144(6): p. 2179-
83.
24. Danser, A.H., Local renin-angiotensin systems: the unanswered questions. Int J Biochem Cell Biol, 2003. 35(6): p. 759-68.
25. Phillips, M.I. and C. Sumners, Angiotensin II in central nervous system physiology.
Regul Pept, 1998. 78(1-3): p. 1-11.
26. Wright, J.W., L.H. Kawas, and J.W. Harding, A Role for the Brain RAS in Alzheimer's and Parkinson's Diseases. Front Endocrinol (Lausanne), 2013. 4: p. 158.
27. Zhuo, J.L. and X.C. Li, New insights and perspectives on intrarenal renin- angiotensin system: focus on intracrine/intracellular angiotensin II. Peptides, 2011. 32(7): p. 1551-65.
28. Murphy, T.J., et al., Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature, 1991. 351(6323): p. 233-6.
29. Mukoyama, M., et al., Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem, 1993. 268(33): p.
24539-42.
30. Sasaki, K., et al., Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature, 1991. 351(6323): p. 230-3.
31. Wright, J.W., B.J. Yamamoto, and J.W. Harding, Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets. Prog Neurobiol, 2008. 84(2): p. 157-81.
32. Saavedra, J.M., Brain and pituitary angiotensin. Endocr Rev, 1992. 13(2): p. 329- 80.
33. Guo, D.F. and T. Inagami, The genomic organization of the rat angiotensin II receptor AT1B. Biochim Biophys Acta, 1994. 1218(1): p. 91-4.
34. Inagami, T., D.F. Guo, and Y. Kitami, Molecular biology of angiotensin II receptors: an overview. J Hypertens Suppl, 1994. 12(10): p. S83-94.
35. Thomas, W.G., T.J. Thekkumkara, and K.M. Baker, Molecular mechanisms of angiotensin II (AT1A) receptor endocytosis. Clin Exp Pharmacol Physiol Suppl, 1996. 3: p. S74-80.
36. von Bohlen und Halbach, O. and D. Albrecht, The CNS renin-angiotensin system.
Cell Tissue Res, 2006. 326(2): p. 599-616.
37. Sayeski, P.P., et al., Angiotensin II signal transduction pathways. Regul Pept, 1998. 78(1-3): p. 19-29.
38. Daniels, D., et al., Angiotensin II stimulates water and NaCl intake through separate cell signalling pathways in rats. Exp Physiol, 2009. 94(1): p. 130-7.
39. Daniels, D., et al., Divergent behavioral roles of angiotensin receptor intracellular signaling cascades. Endocrinology, 2005. 146(12): p. 5552-60.
132 40. Hunyady, L. and K.J. Catt, Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol, 2006. 20(5): p. 953-70.
41. Claing, A., et al., Endocytosis of G protein-coupled receptors: roles of G protein- coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol, 2002. 66(2): p. 61-79.
42. Saavedra, J.M., et al., Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists. Regul Pept, 2005. 128(3): p. 227-38.
43. Saavedra, J.M., et al., A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding. Neuropsychopharmacology, 2006. 31(6): p. 1123-34.
44. Saavedra, J.M., J. Benicky, and J. Zhou, Mechanisms of the Anti-Ischemic Effect of Angiotensin II AT( 1 ) Receptor Antagonists in the Brain. Cell Mol Neurobiol, 2006. 26(7-8): p. 1099-111.
45. Paul, M., A. Poyan Mehr, and R. Kreutz, Physiology of local renin-angiotensin systems. Physiol Rev, 2006. 86(3): p. 747-803.
46. Phillips, M.I. and E.M. de Oliveira, Brain renin angiotensin in disease. J Mol Med (Berl), 2008. 86(6): p. 715-22.
47. Bader, M., Tissue renin-angiotensin-aldosterone systems: Targets for
pharmacological therapy. Annu Rev Pharmacol Toxicol, 2010. 50: p. 439-65.
48. Kakar, S.S., K.K. Riel, and J.D. Neill, Differential expression of angiotensin II receptor subtype mRNAs (AT-1A and AT-1B) in the brain. Biochem Biophys Res Commun, 1992. 185(2): p. 688-92.
49. Mendelsohn, F.A., et al., Autoradiographic localization of angiotensin II receptors in rat brain. Proc Natl Acad Sci U S A, 1984. 81(5): p. 1575-9.
50. Jugdutt, B.I., Valsartan in the treatment of heart attack survivors. Vasc Health Risk Manag, 2006. 2(2): p. 125-38.
51. Seltzer, A., et al., Oral administration of an AT1 receptor antagonist prevents the central effects of angiotensin II in spontaneously hypertensive rats. Brain Res, 2004. 1028(1): p. 9-18.
52. Vauquelin, G., F. Fierens, and I. Van Liefde, Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl- tetrazole sartans. J Hypertens Suppl, 2006. 24(1): p. S23-30.
53. Ferguson, A.V. and N.W. Kasting, Angiotensin acts at the subfornical organ to increase plasma oxytocin concentrations in the rat. Regul Pept, 1988. 23(3): p. 343-52.
54. Ferguson, A.V., D.L. Washburn, and K.J. Latchford, Hormonal and
neurotransmitter roles for angiotensin in the regulation of central autonomic function. Exp Biol Med (Maywood), 2001. 226(2): p. 85-96.
55. Ferguson, A.V. and J.S. Bains, Actions of angiotensin in the subfornical organ and area postrema: implications for long term control of autonomic output. Clin Exp Pharmacol Physiol, 1997. 24(1): p. 96-101.
56. Zhuo, J., et al., Mapping tissue angiotensin-converting enzyme and angiotensin AT1, AT2 and AT4 receptors. J Hypertens, 1998. 16(12 Pt 2): p. 2027-37.
57. McKinley, M.J., et al., The brain renin-angiotensin system: location and physiological roles. Int J Biochem Cell Biol, 2003. 35(6): p. 901-18.
58. Llorens-Cortes, C. and F.A. Mendelsohn, Organisation and functional role of the brain angiotensin system. J Renin Angiotensin Aldosterone Syst, 2002. 3 Suppl 1:
133 59. Antunes-Rodrigues, J., et al., Neuroendocrine control of body fluid metabolism.
Physiol Rev, 2004. 84(1): p. 169-208.
60. Stornetta, R.L., et al., Astrocytes synthesize angiotensinogen in brain. Science, 1988. 242(4884): p. 1444-6.
61. Richoux, J.P., et al., The renin-angiotensin system in the rat brain.
Immunocytochemical localization of angiotensinogen in glial cells and neurons.
Histochemistry, 1988. 89(4): p. 323-31.
62. Ohkubo, H., et al., Tissue distribution of rat angiotensinogen mRNA and structural analysis of its heterogeneity. J Biol Chem, 1986. 261(1): p. 319-23.
63. Yang, G., et al., The angiotensinogen gene is expressed in both astrocytes and neurons in murine central nervous system. Brain Res, 1999. 817(1-2): p. 123-31.
64. Ganong, W.F., The brain renin-angiotensin system. Annu Rev Physiol, 1984. 46: p.
17-31.
65. Moffett, R.B., F.M. Bumpus, and A. Husain, Cellular organization of the brain renin-angiotensin system. Life Sci, 1987. 41(16): p. 1867-79.
66. Morimoto, S., M.D. Cassell, and C.D. Sigmund, The brain renin-angiotensin system in transgenic mice carrying a highly regulated human renin transgene. Circ Res, 2002. 90(1): p. 80-6.
67. Rix, E., et al., Converting-enzyme in the choroid plexus, brain, and kidney: immunocytochemical and biochemical studies in rats. Neurosci Lett, 1981. 22(2): p. 125-30.
68. Beckmann, H., J.M. Saavedra, and W.F. Gattaz, Low angiotensin-converting enzyme activity (kininase II) in cerebrospinal fluid of schizophrenics. Biol Psychiatry, 1984. 19(5): p. 679-84.
69. Caldwell, P.R., et al., Angiotensin-converting enzyme: vascular endothelial localization. Science, 1976. 191(4231): p. 1050-1.
70. Mendelsohn, F.A., et al., The brain angiotensin system: insights from mapping its components. Trends Endocrinol Metab, 1990. 1(4): p. 189-98.
71. Pickel, V.M., J. Chan, and D. Ganten, Dual peroxidase and colloidal gold-labeling study of angiotensin converting enzyme and angiotensin-like immunoreactivity in the rat subfornical organ. J Neurosci, 1986. 6(8): p. 2457-69.
72. Tipnis, S.R., et al., A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem, 2000. 275(43): p. 33238-43.
73. Feng, Y., et al., Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ Res, 2008. 102(6): p. 729-36.
74. Feng, Y., et al., Angiotensin-converting enzyme 2 over-expression in the central nervous system reduces angiotensin-II-mediated cardiac hypertrophy. PLoS One, 2012. 7(11): p. e48910.
75. Lind, R.W., L.W. Swanson, and D. Ganten, Organization of angiotensin II immunoreactive cells and fibers in the rat central nervous system. An immunohistochemical study. Neuroendocrinology, 1985. 40(1): p. 2-24.
76. Sumners, C., et al., Physiological and pharmacological comparisons of angiotensin II receptors in neuronal and astrocyte glial cultures. Prog Neurobiol, 1990. 34(5): p. 355-85.
77. Simonnet, G., et al., Location of angiotensin II binding sites on neuronal and glial cells of cultured mouse spinal cord: an autoradiographic study. Brain Res, 1988. 443(1-2): p. 403-6.
134 78. Fogarty, D.J. and C. Matute, Angiotensin receptor-like immunoreactivity in adult
brain white matter astrocytes and oligodendrocytes. Glia, 2001. 35(2): p. 131-46.
79. Hall, J.E. and M.W. Brands, The renin-angiotensin-aldosterone systems, in The Kidney: Physiology and Pathophysiology, D.W.y.G. Seldin, G., Editor. 2000, Lippincott Williams & Wilkins.
80. Weiss, M.L., K.E. Moe, and A.N. Epstein, Interference with central actions of angiotensin II suppresses sodium appetite. Am J Physiol, 1986. 250(2 Pt 2): p. R250-9.
81. Muntzel, M., et al., Selective effects of sodium and chloride depletion on salt appetite in rats. Am J Physiol, 1991. 261(3 Pt 2): p. R603-8.
82. Epstein, A.N., The dependence of the salt appetite of the rat on the hormonal consequences of sodium deficiency. J Physiol (Paris), 1984. 79(6): p. 496-8.
83. Unger, T., et al., Natriuretic action of central angiotensin II in conscious rats.
Brain Res, 1989. 486(1): p. 33-8.
84. Phillips, M.I., Functions of angiotensin in the central nervous system. Annu Rev Physiol, 1987. 49: p. 413-35.
85. Fluharty, S.J. and A.N. Epstein, Sodium appetite elicited by intracerebroventricular infusion of angiotensin II in the rat: II. Synergistic interaction with systemic mineralocorticoids. Behav Neurosci, 1983. 97(5): p. 746-58.
86. Fluharty, S.J. and S. Manaker, Sodium appetite elicited by intracerebroventricular infusion of angiotensin II in the rat: I. Relation to urinary sodium excretion. Behav Neurosci, 1983. 97(5): p. 738-45.
87. Ray, P.E., et al., Different effects of sodium or chloride depletion on angiotensin II receptors in rats. Am J Physiol, 1990. 258(4 Pt 2): p. R1008-15.
88. Ray, P.E., E.J. Ruley, and J.M. Saavedra, Down-regulation of angiotensin II receptors in subfornical organ of young male rats by chronic dietary sodium depletion. Brain Res, 1990. 510(2): p. 303-8.
89. Mann, J.F., et al., Central actions and brain receptor binding of angiotensin II: Influence of sodium intake. Hypertension, 1980. 2(4): p. 437-43.
90. Meldrum, M.J. and T.C. Westfall, Angiotensin facilitation of 3H-norepinephrine release in central tissue of spontaneously hypertensive rats but not in Wistar-Kyoto rats: effects of sodium depletion. J Cardiovasc Pharmacol, 1986. 8(3): p. 582-7.
91. Gutkind, J.S., M. Kurihara, and J.M. Saavedra, Increased angiotensin II receptors in brain nuclei of DOCA-salt hypertensive rats. Am J Physiol, 1988. 255(3 Pt 2): p.
H646-50.
92. McKinley, M.J., et al., Effects of central losartan on plasma renin and centrally mediated natriuresis. Kidney Int, 1994. 46(6): p. 1479-82.
93. Weekley, L.B., Renal renin secretion rate and norepinephrine secretion rate in response to centrally administered angiotensin-II: role of the medial basal forebrain. Clin Exp Hypertens A, 1992. 14(5): p. 923-45.
94. Allen, A.M., et al., Angiotensin II receptors in the human brain. Regul Pept, 1999. 79(1): p. 1-7.
95. Barnes, J.M., et al., Identification and characterisation of angiotensin II receptor subtypes in human brain. Eur J Pharmacol, 1993. 230(3): p. 251-8.
96. Tsutsumi, K. and J.M. Saavedra, Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol, 1991. 261(1 Pt 2): p. R209-16.
97. Johren, O., T. Inagami, and J.M. Saavedra, AT1A, AT1B, and AT2 angiotensin II receptor subtype gene expression in rat brain. Neuroreport, 1995. 6(18): p. 2549- 52.
135 98. Johren, O., T. Inagami, and J.M. Saavedra, Localization of AT2 angiotensin II receptor gene expression in rat brain by in situ hybridization histochemistry. Brain Res Mol Brain Res, 1996. 37(1-2): p. 192-200.
99. Johren, O. and J.M. Saavedra, Gene expression of angiotensin II receptor subtypes in the cerebellar cortex of young rats. Neuroreport, 1996. 7(8): p. 1349-52.
100. Gard, P.R., The role of angiotensin II in cognition and behaviour. Eur J Pharmacol, 2002. 438(1-2): p. 1-14.
101. Wright, J.W. and J.W. Harding, Brain renin-angiotensin--a new look at an old system. Prog Neurobiol, 2011. 95(1): p. 49-67.
102. Tchekalarova, J., et al., The effects of sarmesin, an Angiotensin II analogue on seizure susceptibility, memory retention and nociception. Regul Pept, 2003. 111(1-
3): p. 191-7.
103. Pederson, E.S., J.W. Harding, and J.W. Wright, Attenuation of scopolamine- induced spatial learning impairments by an angiotensin IV analog. Regul Pept, 1998. 74(2-3): p. 97-103.
104. Tota, S., et al., Effect of angiotensin II on spatial memory, cerebral blood flow, cholinergic neurotransmission, and brain derived neurotrophic factor in rats.
Psychopharmacology (Berl), 2013. 226(2): p. 357-69.
105. Denny, J.B., et al., Angiotensin II blocks hippocampal long-term potentiation.
Brain Res, 1991. 567(2): p. 321-4.
106. Georgiev, V., D. Getova, and M. Opitz, Mechanisms of the angiotensin II effects on the exploratory behavior of rats in open field. I. Interaction of angiotensin II with saralasin and catecholaminergic drugs. Methods Find Exp Clin Pharmacol, 1987. 9(5): p. 297-301.
107. Premer, C., et al., Immunohistochemical Localization of AT1a, AT1b, and AT2 Angiotensin II Receptor Subtypes in the Rat Adrenal, Pituitary, and Brain with a Perspective Commentary. Int J Hypertens, 2013. 2013: p. 175428.
108. Armando, I., et al., Peripheral administration of an angiotensin II AT(1) receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation Stress. Endocrinology, 2001. 142(9): p. 3880-9.
109. Baiardi, G., et al., Angiotensin II AT1 receptor blockade prolongs the lifespan of spontaneously hypertensive rats and reduces stress-induced release of catecholamines, glucocorticoids, and vasopressin. Ann N Y Acad Sci, 2004. 1018:
p. 131-6.
110. Jezova, D., et al., Brain angiotensin II modulates sympathoadrenal and hypothalamic pituitary adrenocortical activation during stress. J Neuroendocrinol, 1998. 10(1): p. 67-72.
111. Armando, I., et al., Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stress. Brain Res, 2007. 1142: p. 92-9.
112. Tsutsumi, K. and J.M. Saavedra, Angiotensin-II receptor subtypes in median eminence and basal forebrain areas involved in regulation of pituitary function.
Endocrinology, 1991. 129(6): p. 3001-8.
113. Yang, G., Y. Wan, and Y. Zhu, Angiotensin II--an important stress hormone. Biol Signals, 1996. 5(1): p. 1-8.
114. Yang, G., et al., Changes in circulating and tissue angiotensin II during acute and chronic stress. Biol Signals, 1993. 2(3): p. 166-72.
115. Castren, E. and J.M. Saavedra, Repeated stress increases the density of angiotensin II binding sites in rat paraventricular nucleus and subfornical organ.
136 116. Shigematsu, K., et al., Angiotensin II binding sites in the anteroventral-third ventricle (AV3V) area and related structures of the rat brain. Neurosci Lett, 1986. 67(1): p. 37-41.
117. Aguilera, G., A. Kiss, and X. Luo, Increased expression of type 1 angiotensin II receptors in the hypothalamic paraventricular nucleus following stress and glucocorticoid administration. J Neuroendocrinol, 1995. 7(10): p. 775-83.
118. Ganong, W.F. and K. Murakami, The role of angiotensin II in the regulation of ACTH secretion. Ann N Y Acad Sci, 1987. 512: p. 176-86.
119. Bregonzio, C., et al., Angiotensin II AT(1) receptor blockade selectively enhances brain AT(2) receptor expression, and abolishes the cold-restraint stress-induced increase in tyrosine hydroxylase mRNA in the locus coeruleus of spontaneously hypertensive rats. Stress, 2008. 11(6): p. 457-66.
120. Okuyama, S., et al., Anxiety-like behavior in mice lacking the angiotensin II type-2 receptor. Brain Res, 1999. 821(1): p. 150-9.
121. Pavel, J., et al., Peripherally administered angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo. Ann N Y Acad Sci, 2008. 1148: p. 360-6.
122. Bremner, J.D., et al., Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder. Am J Psychiatry, 2000. 157(7): p. 1120-6.
123. Keck, M.E. and F. Holsboer, Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides, 2001. 22(5): p. 835-44.
124. Barnes, N.M., et al., Anxiolytic-like action of DuP753, a non-peptide angiotensin II receptor antagonist. Neuroreport, 1990. 1(1): p. 20-1.
125. Kaiser, F.C., et al., Antianxiety properties of the angiotensin II antagonist, DUP 753, in the rat using the elevated plus-maze. Neuroreport, 1992. 3(10): p. 922-4.
126. Korte, S.M. and S.F. De Boer, A robust animal model of state anxiety: fear- potentiated behaviour in the elevated plus-maze. Eur J Pharmacol, 2003. 463(1-3):
p. 163-75.
127. Millan, M.J., et al., Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent. Neuropsychopharmacology, 2001. 25(4): p. 585-600.
128. Shekhar, A., et al., The amygdala, panic disorder, and cardiovascular responses.
Ann N Y Acad Sci, 2003. 985: p. 308-25.
129. Goeders, N.E., Stress and cocaine addiction. J Pharmacol Exp Ther, 2002. 301(3):
p. 785-9.
130. Rouge-Pont, F., et al., Stress-induced sensitization and glucocorticoids. II. Sensitization of the increase in extracellular dopamine induced by cocaine depends on stress-induced corticosterone secretion. J Neurosci, 1995. 15(11): p. 7189-95.
131. Piazza, P.V. and M. Le Moal, The role of stress in drug self-administration. Trends Pharmacol Sci, 1998. 19(2): p. 67-74.
132. Piazza, P.V., et al., Stress, glucocorticoids, and mesencephalic dopaminergic neurons: a pathophysiological chain determining vulnerability to psychostimulant abuse. NIDA Res Monogr, 1996. 163: p. 277-99.
133. Dole, V.P. and M.E. Nyswander, Rehabilitation of heroin addicts after blockade with methadone. N Y State J Med, 1966. 66(15): p. 2011-7.
134. Kreek, M.J., Effects of opiates, opioid antagonists and cocaine on the endogenous opioid system: clinical and laboratory studies. NIDA Res Monogr, 1992. 119: p. 44-8.
135. Kreek, M.J. and G.F. Koob, Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend, 1998. 51(1-2): p. 23-47.
137 136. Piazza, P.V., et al., Corticosterone in the range of stress-induced levels possesses reinforcing properties: implications for sensation-seeking behaviors. Proc Natl Acad Sci U S A, 1993. 90(24): p. 11738-42.
137. Goeders, N.E., Stress, the hypothalamic-pituitary-adrenal axis, and vulnerability to drug abuse. NIDA Res Monogr, 1998. 169: p. 83-104.
138. Vanderschuren, L.J., et al., A single exposure to amphetamine is sufficient to induce long-term behavioral, neuroendocrine, and neurochemical sensitization in rats. J Neurosci, 1999. 19(21): p. 9579-86.
139. Pierce, R.C. and P.W. Kalivas, A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Brain Res Rev, 1997. 25(2): p. 192-216.
140. Vanderschuren, L.J. and P.W. Kalivas, Alterations in dopaminergic and
glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl), 2000. 151(2-3): p. 99-120.
141. Abercrombie, E.D., et al., Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem, 1989. 52(5): p. 1655-8.
142. Imperato, A., et al., Repeated stressful experiences differently affect limbic dopamine release during and following stress. Brain Res, 1992. 577(2): p. 194-9.
143. Berridge, K.C. and T.E. Robinson, What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev, 1998. 28(3): p. 309-69.
144. Ikemoto, S. and J. Panksepp, The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res Brain Res Rev, 1999. 31(1): p. 6-41.
145. Lorrain, D.S., G.M. Arnold, and P. Vezina, Previous exposure to amphetamine increases incentive to obtain the drug: long-lasting effects revealed by the progressive ratio schedule. Behav Brain Res, 2000. 107(1-2): p. 9-19.
146. Di Chiara, G. and A. Imperato, Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.
Proc Natl Acad Sci U S A, 1988. 85(14): p. 5274-8.
147. Georgiev, V., et al., Some central effects of angiotensin II. Interactions with dopaminergic transmission. Acta Physiol Pharmacol Bulg, 1985. 11(4): p. 19-26.
148. Huang, B.S. and R.L. Malvin, Dopaminergic modulation of some central actions of angiotensin II in vivo. Proc Soc Exp Biol Med, 1988. 188(4): p. 405-9.
149. Tchekalarova, J. and V. Georgiev, Further evidence for interaction between angiotensin II and dopamine receptors (experiments on apomorphine stereotypy).
Methods Find Exp Clin Pharmacol, 1998. 20(5): p. 419-24.
150. Daubert, D.L., et al., Changes in angiotensin II receptors in dopamine-rich regions of the mouse brain with age and ethanol consumption. Brain Res, 1999. 816(1): p.
8-16.
151. White, F.J. and P.W. Kalivas, Neuroadaptations involved in amphetamine and cocaine addiction. Drug Alcohol Depend, 1998. 51(1-2): p. 141-53.
152. Brown, D.C., et al., Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br J Pharmacol, 1996. 118(2): p. 414-20.
153. Hoebel, B.G., et al., The power of integrative peptides to reinforce behavior by releasing dopamine. Ann N Y Acad Sci, 1994. 739: p. 36-41.
138 154. Raghavendra, V., K. Chopra, and S.K. Kulkarni, Modulation of motor functions involving the dopaminergic system by AT1 receptor antagonist, losartan.
Neuropeptides, 1998. 32(3): p. 275-80.
155. Kalivas, P.W., Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate neuroplasticity. Dialogues Clin Neurosci, 2007. 9(4): p. 389-97.
156. Robinson, T.E. and B. Kolb, Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology, 2004. 47 Suppl 1: p. 33-46.
157. Soetens, E., R. D'Hooge, and J.E. Hueting, Amphetamine enhances human-memory
consolidation. Neurosci Lett, 1993. 161(1): p. 9-12.
158. Wood, S.C. and S.G. Anagnostaras, Memory and psychostimulants: modulation of
Pavlovian fear conditioning by amphetamine in C57BL/6 mice.
Psychopharmacology (Berl), 2009. 202(1-3): p. 197-206.
159. Xue, B., et al., Sensitization of slow pressor angiotensin II (Ang II)-initiated hypertension: induction of sensitization by prior Ang II treatment. Hypertension, 2012. 59(2): p. 459-66.
160. Na, E.S., et al., The neural substrates of enhanced salt appetite after repeated sodium depletions. Brain Res, 2007. 1171: p. 104-10.
161. Clark, J.J. and I.L. Bernstein, Reciprocal cross-sensitization between amphetamine and salt appetite. Pharmacol Biochem Behav, 2004. 78(4): p. 691-8.
162. Roitman, M.F., et al., Induction of a salt appetite alters dendritic morphology in